NASDAQ · ICCM
Healthcare · Medical - Devices
$2.06
Down-$0.07 (-3.40%)
Updated Sep 17, 2026, 9:29 PM
SID Score
4.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
ICCM closed at $2.06 after 20 trading sessions, down 18.25% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $2.06 | $2.14 | $2.02 | $2.06 | 81.47K |
| Sep 15, 2026 | $2.12 | $2.14 | $2.04 | $2.05 | 95.37K |
| Sep 14, 2026 | $2.21 | $2.21 | $2.09 | $2.09 | 73.8K |
| Sep 11, 2026 | $2.13 | $2.50 | $2.10 | $2.21 | 211.9K |
| Sep 10, 2026 | $2.08 | $2.20 | $2.06 | $2.14 | 278.95K |
| Sep 9, 2026 | $2.21 | $2.21 | $2.10 | $2.11 | 67.12K |
| Sep 8, 2026 | $2.25 | $2.25 | $2.14 | $2.21 | 54K |
| Sep 4, 2026 | $2.20 | $2.245 | $2.13 | $2.23 | 58.44K |
| Sep 3, 2026 | $2.27 | $2.27 | $2.16 | $2.20 | 49.96K |
| Sep 2, 2026 | $2.27 | $2.28 | $2.15 | $2.26 | 71.34K |
| Sep 1, 2026 | $2.33 | $2.33 | $2.21 | $2.28 | 49.78K |
| Aug 31, 2026 | $2.33 | $2.33 | $2.24 | $2.28 | 64.43K |
| Aug 28, 2026 | $2.36 | $2.36 | $2.20 | $2.30 | 84.9K |
| Aug 27, 2026 | $2.33 | $2.33 | $2.20 | $2.29 | 90.11K |
| Aug 26, 2026 | $2.30 | $2.32 | $2.20 | $2.29 | 98.42K |
| Aug 25, 2026 | $2.33 | $2.35 | $2.20 | $2.28 | 110.81K |
| Aug 24, 2026 | $2.38 | $2.38 | $2.18 | $2.27 | 656.68K |
| Aug 21, 2026 | $2.49 | $2.50 | $2.31 | $2.43 | 107.49K |
| Aug 20, 2026 | $2.52 | $2.65 | $2.30 | $2.45 | 992.79K |
| Aug 19, 2026 | $2.71 | $2.7999 | $2.48 | $2.52 | 67.3K |
The latest Smart Investors Daily articles mentioning ICCM.
ICCM research
Company profile and research snapshot.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 14, 2026 | Maxim Group | Buy | — |
| Oct 7, 2025 | HC Wainwright & Co. | Buy | — |
| Aug 15, 2025 | HC Wainwright & Co. | Buy | — |
| May 29, 2025 | HC Wainwright & Co. | Buy | — |
| Mar 28, 2025 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Sep 10, 2026
IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to
Benzinga · Aug 24, 2026
IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to
Benzinga · Aug 20, 2026
Patients are expected to enroll in the post-marketing study in the coming weeks, following approval from the Institutional Review Board of West Cancer Center & Research Institute in Germantown, TNCAESAREA, Israel,
Benzinga · Aug 13, 2026
New review by leading U.S. experts highlights ProSense® FDA marketing authorization, updated American Society of Breast Surgeons guidelines, and encouraging outcomes from the five-year ICE3 clinical trial while a second
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ICCM.
